ESR1 and breast cancer: These advantages have established neoadjuvant chemotherapy (NCT) as a widely accepted approach to estrogen receptor negative (ER−) tumors, but neoadjuvant endocrine therapy (NET) still remains an underutilized tool for ER+ breast cancers, and is frequently relegated to the treatment of elderly or frail patients who are not candidates for chemotherapy.